Nuvalent to Participate in Upcoming March Investor Conferences

Rhea-AI Summary

Nuvalent (Nasdaq: NUVL), a clinical-stage biopharmaceutical company developing targeted cancer therapies, has announced its participation in three major investor conferences this March 2025. CEO James Porter, Ph.D., and CFO Alexandra Balcom will engage in fireside chats at:

• TD Cowen 45th Annual Health Care Conference - March 5, 9:50 a.m. ET (Boston)
• Leerink Global Healthcare Conference 2025 - March 10, 10:40 a.m. ET (Miami)
• Barclays 27th Annual Global Healthcare Conference - March 12, 2:30 p.m. ET (Miami)

Live webcasts will be accessible through Nuvalent's website investor section and remain archived for 30 days post-presentation.

News Market Reaction

+0.09%

1 alert

+0.09% News Effect

On the day this news was published, NUVL gained 0.09%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

CAMBRIDGE, Mass., Feb. 28, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer, and Alexandra Balcom, Chief Financial Officer, will participate in fireside chats during the following March investor conferences:

• TD Cowen 45^th Annual Health Care Conference on Wednesday, March 5, 2025 at 9:50 a.m. ET in Boston;
• Leerink Global Healthcare Conference 2025 on Monday, March 10, 2025 at 10:40 a.m. ET in Miami, FL; and,
• Barclays 27^th Annual Global Healthcare Conference on Wednesday, March 12, 2025 at 2:30 p.m. ET in Miami, FL.

Live webcasts will be available in the Investors section of the company's website at www.nuvalent.com, and archived for 30 days following the presentations.

About Nuvalent
Nuvalent, Inc. (Nasdaq: NUVL) is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, we develop innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, and multiple discovery-stage research programs.

View original content to download multimedia:https://www.prnewswire.com/news-releases/nuvalent-to-participate-in-upcoming-march-investor-conferences-302388052.html

SOURCE Nuvalent, Inc.

FAQ

When is Nuvalent (NUVL) presenting at the TD Cowen Healthcare Conference in March 2025?

Nuvalent will present at the TD Cowen Conference on March 5, 2025, at 9:50 a.m. ET in Boston.

How can investors watch Nuvalent's (NUVL) March 2025 conference presentations?

Investors can watch live webcasts through Nuvalent's website (www.nuvalent.com) in the Investors section, with recordings available for 30 days after presentations.

Which executives will represent Nuvalent (NUVL) at the March 2025 investor conferences?

CEO James Porter, Ph.D., and CFO Alexandra Balcom will represent Nuvalent at the conferences.

What investor conferences is Nuvalent (NUVL) attending in Miami during March 2025?

Nuvalent is attending two Miami conferences: the Leerink Global Healthcare Conference on March 10 and the Barclays Global Healthcare Conference on March 12, 2025.